Iversen P, Christensen M G, Friis E, Hornbøl P, Hvidt V, Iversen H G, Klarskov P, Krarup T, Lund F, Mogensen P
Department of Urology, Hvidovre Hospital, Denmark.
Cancer. 1990 Sep 1;66(5 Suppl):1058-66. doi: 10.1002/cncr.1990.66.s5.1058.
In a multicenter Phase III trial 264 patients with advanced prostatic cancer were randomized to either bilateral orchiectomy or treatment with zoladex supplemented by flutamide. Presently, median follow-up time is 30 months. A small difference in objective response was recorded in favor of the combination therapy, whereas no statistically significant difference was found in subjective response to therapy, time to progression, and overall survival. Adverse effects were more commonly encountered in the pharmacologically treated patients. It is concluded that the combination of zoladex plus flutamide is not clinically superior to orchiectomy in the treatment of patients with advanced carcinoma of the prostate.
在一项多中心III期试验中，264例晚期前列腺癌患者被随机分为双侧睾丸切除术组或戈舍瑞林辅以氟他胺治疗组。目前，中位随访时间为30个月。记录到客观反应存在微小差异，支持联合治疗，但在治疗的主观反应、疾病进展时间和总生存期方面未发现统计学上的显著差异。药物治疗组更常出现不良反应。结论是，在治疗晚期前列腺癌患者方面，戈舍瑞林加氟他胺的联合治疗在临床上并不优于睾丸切除术。
